Real-World Study of 294,499 Veterans Aged 65 and Older: mNEXSPIKE Shows 35.9 Percent Relative Effectiveness, Published in JAMA Network Open on November 11
CAMBRIDGE, Massachusetts — Moderna, Inc. announced on November 11 the publication in JAMA Network Open of a large real-world study evaluating the comparative effectiveness of its COVID-19 vaccine mNEXSPIKE and Comirnaty among U.S. Veterans aged 65 years and older during the 2025-2026 respiratory virus season. The analysis included 294,499 matched participants in the U.S. Veterans Health Administration (VHA). This item reports the study's facts only and offers no individual medical advice.
The study's primary outcome was medically attended COVID-19, including hospitalization, emergency room visits, urgent care, outpatient visits and antiviral treatment. mNEXSPIKE was associated with 35.9 percent relative vaccine effectiveness against medically attended COVID-19 compared with Comirnaty (95 percent CI: 20.4 to 49.7 percent), and with 47.0 percent relative vaccine effectiveness against COVID-19-associated hospitalization (95 percent CI: 5.4 to 74.8 percent), with point estimates consistently favoring mNEXSPIKE across all individual components. An exploratory analysis found 39.3 percent relative vaccine effectiveness for hospitalization involving a major adverse cardiovascular event (95 percent CI: 11.8 to 57.0 percent).
The retrospective, active-comparator matched cohort study included VHA-enrolled veterans aged 65 years and older who received an LP.8.1-formulated mNEXSPIKE or Comirnaty vaccine between August 27, 2025 and January 31, 2026, followed for up to 150 days or through May 1, 2026, matched by home county and calendar week of vaccination. The company and investigators note that, as an observational real-world analysis, the study is subject to residual confounding, including differences in testing behavior, undocumented prior infection and vaccine availability; that the predominantly older, male VHA population may limit generalizability; and that the findings are associative and do not establish causality. The study was supported by Moderna, which contributed to study design, data interpretation and manuscript work, while Moderna did not conduct the study or collect, manage or analyze the data.
Source: Moderna
Published by GSM · USA (original Chinese edition)
Photo: 图：退伍军人医院（资料图）。经Wikimedia Commons。 / Photo: a veterans hospital (file photo). Via Wikimedia Commons.
